EA201201661A1 - Новые аминопиразолохиназолины - Google Patents
Новые аминопиразолохиназолиныInfo
- Publication number
- EA201201661A1 EA201201661A1 EA201201661A EA201201661A EA201201661A1 EA 201201661 A1 EA201201661 A1 EA 201201661A1 EA 201201661 A EA201201661 A EA 201201661A EA 201201661 A EA201201661 A EA 201201661A EA 201201661 A1 EA201201661 A1 EA 201201661A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- aminopyrazolohinazolines
- new
- compounds
- medicines
- excessive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к соединениям общей формулы (I), в которой группы R-Rи X являются такими, как определено в п.1 формулы изобретения, которые являются подходящими для лечения заболеваний, характеризующихся чрезмерной или аномальной пролиферацией клеток, к фармацевтическим препаратам, которые содержат такие соединения, и к их применению в качестве лекарственных средств.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170683 | 2010-07-23 | ||
PCT/EP2011/062683 WO2012010704A1 (en) | 2010-07-23 | 2011-07-22 | New aminopyrazoloquinazolines |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201201661A1 true EA201201661A1 (ru) | 2013-07-30 |
Family
ID=43037625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201661A EA201201661A1 (ru) | 2010-07-23 | 2011-07-22 | Новые аминопиразолохиназолины |
Country Status (22)
Country | Link |
---|---|
US (1) | US8735386B2 (ru) |
EP (1) | EP2595987B1 (ru) |
JP (1) | JP5991974B2 (ru) |
KR (1) | KR20130132394A (ru) |
CN (1) | CN103097388A (ru) |
AP (1) | AP2012006640A0 (ru) |
AR (1) | AR082850A1 (ru) |
AU (1) | AU2011281504A1 (ru) |
BR (1) | BR112013000107A2 (ru) |
CA (1) | CA2803467A1 (ru) |
CL (1) | CL2012003745A1 (ru) |
CO (1) | CO6670575A2 (ru) |
EA (1) | EA201201661A1 (ru) |
EC (1) | ECSP13012448A (ru) |
GE (1) | GEP20156289B (ru) |
MA (1) | MA34389B1 (ru) |
MX (1) | MX2013000821A (ru) |
PE (1) | PE20131143A1 (ru) |
SG (1) | SG187548A1 (ru) |
TW (1) | TW201217380A (ru) |
UY (1) | UY33526A (ru) |
WO (1) | WO2012010704A1 (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6128133B2 (ja) * | 2012-01-23 | 2017-05-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Igf−1r/ir阻害剤としての5,8−ジヒドロ−6h−ピラゾロ[3,4−h]キナゾリン |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
ES2724331T3 (es) * | 2013-11-15 | 2019-09-10 | Oncoceutics Inc | 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso |
MA55402A (fr) | 2015-01-30 | 2022-02-02 | Oncoceutics Inc | Dérivés de 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, leurs sels et leur utilisation en thérapie |
EP3294742B1 (en) * | 2015-05-13 | 2020-01-08 | Boehringer Ingelheim International GmbH | New (5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h)quinazolin-2-yl)-(1h-pyrazol-5-yl)-amines and theri derivatives as igf-1r/1r inhibitors. |
AU2017356569B2 (en) * | 2016-11-11 | 2020-10-08 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof |
DK3632904T3 (da) * | 2017-05-26 | 2022-07-25 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | URAT1-inhibitorer til at fremme urinsyreudskillelse |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
JP2021521282A (ja) * | 2018-04-24 | 2021-08-26 | 上海海雁医薬科技有限公司Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Cdk4/6阻害剤、その薬学的に許容可能な塩と結晶多形体、及びその応用 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
CA3128200A1 (en) * | 2019-01-30 | 2020-08-06 | Yale University | Compounds, compositions, and methods for treating fibrosis |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
CA3132229A1 (en) * | 2019-03-07 | 2020-09-10 | BioNTech SE | Process for the preparation of a substituted imidazoquinoline |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020214889A1 (en) * | 2019-04-19 | 2020-10-22 | Fount Bio, Inc. | Delivery and retention of active agents within the skin |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
EP4013750A1 (en) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
WO2022166725A1 (zh) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 5,6-二氢噻吩并[3,4-h]喹唑啉类化合物 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997012880A1 (en) * | 1995-10-02 | 1997-04-10 | F.Hoffmann-La Roche Ag | Pyrimidine derivatives as 5ht2c-receptor antagonists |
RS52899B (en) | 2003-05-22 | 2014-02-28 | Nerviano Medical Sciences S.R.L. | PIRAZOLO-HINAZOLINE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/en active Active
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 CA CA2803467A patent/CA2803467A1/en not_active Abandoned
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/en active Application Filing
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Application Discontinuation
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2595987A1 (en) | 2013-05-29 |
UY33526A (es) | 2012-02-29 |
CN103097388A (zh) | 2013-05-08 |
WO2012010704A1 (en) | 2012-01-26 |
CL2012003745A1 (es) | 2013-05-31 |
GEP20156289B (en) | 2015-05-25 |
CA2803467A1 (en) | 2012-01-26 |
PE20131143A1 (es) | 2013-10-23 |
US8735386B2 (en) | 2014-05-27 |
AR082850A1 (es) | 2013-01-16 |
JP2013532652A (ja) | 2013-08-19 |
MX2013000821A (es) | 2013-05-30 |
KR20130132394A (ko) | 2013-12-04 |
AU2011281504A1 (en) | 2013-01-10 |
BR112013000107A2 (pt) | 2016-05-17 |
SG187548A1 (en) | 2013-03-28 |
TW201217380A (en) | 2012-05-01 |
AP2012006640A0 (en) | 2012-12-31 |
JP5991974B2 (ja) | 2016-09-14 |
MA34389B1 (fr) | 2013-07-03 |
CO6670575A2 (es) | 2013-05-15 |
EP2595987B1 (en) | 2018-04-18 |
ECSP13012448A (es) | 2013-03-28 |
US20120238542A1 (en) | 2012-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201201661A1 (ru) | Новые аминопиразолохиназолины | |
EA201500536A1 (ru) | Триазолопиразин | |
EA201300874A1 (ru) | Новые азаиндолилфенилсульфонамиды в качестве ингибиторов серин/треонинкиназы | |
EA201201030A1 (ru) | 5-алкинилпиримидины | |
CY1118859T1 (el) | 6-αλκινυλο-πυριδινες ως μιμητες smac | |
EA201200552A1 (ru) | Производные пиримидина в качестве ингибиторов протеинтирозинкиназы 2 | |
EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
PH12015501385A1 (en) | Autotaxin inhibitors | |
EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
EA201391106A1 (ru) | Новые гетероциклические производные | |
EA201201665A1 (ru) | Новые соединения | |
EA201692280A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201101330A1 (ru) | Замещенные пиримидины, предназначенные для лечения рака | |
EA201500394A1 (ru) | Ингибиторы деметилаз гистонов | |
EA201590879A1 (ru) | Арилконденсированные и гетероарилконденсированные лактамы | |
EA201100564A1 (ru) | Антипролиферативные соединения | |
EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
EA201490888A1 (ru) | Новые производные пурина и их применение для лечения заболевания | |
EA201100794A1 (ru) | Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак | |
EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
EA201000105A1 (ru) | Химические соединения | |
EA201391786A1 (ru) | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
EA201590562A1 (ru) | Бензамиды |